Palmatine Shows Promise Against Diabetes-Linked Fatty Liver Disease in Preclinical Study

A new preclinical study indicates that palmatine, a natural compound, may alleviate diabetes-linked fatty liver disease by addressing inflammation, oxidative stress, and liver cell death through multiple biological pathways. The research was published in Scientific Reports.

MASLD and Type 2 Diabetes

More than 50% of individuals with Type 2 Diabetes Mellitus (T2DM) also develop Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This co-occurrence significantly increases liver damage and the risk of cirrhosis and cardiovascular complications. Fatty liver disease is characterized by fat accumulation, inflammation, insulin resistance, and liver cell damage. Current treatments often target only a few mechanisms of the disease, leaving a need for more comprehensive approaches.

Study Methodology

Researchers employed a combination of bioinformatics analysis and experimental validation to investigate palmatine's effects. Drug targets were identified using various databases, and disease-related genes for MASLD and apoptosis were obtained. Overlapping targets were then identified, and gene expression data was analyzed.

Machine learning methods were utilized to pinpoint important genes, while functional enrichment analyses examined associated biological pathways. Single-cell sequencing determined gene expression patterns, and immune infiltration, cell-death patterns, pseudotime, and RNA velocity analyses contextualized candidate targets within the liver microenvironment.

For experimental validation, an animal model of T2DM-associated MASLD was created in rats using a high-fat diet and streptozotocin injection. Rats were subsequently divided into groups for blank, model, semaglutide, and low-, medium-, and high-dose palmatine treatments, which were administered for four weeks.

Key Molecular Findings

Bioinformatics analysis revealed 138 overlapping targets between palmatine and MASLD, which were further refined to 43 key genes. Functional enrichment analysis showed dominant pathways related to lipid metabolism, inflammatory response, and apoptosis.

Machine learning models identified five core targets: Adrenoceptor Beta 2 (ADRB2), B-Cell Lymphoma 3 (BCL3), Early Growth Response 1 (EGR1), Fos Proto-Oncogene (FOS), and Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8). Molecular docking suggested palmatine's high binding affinity to these proteins.

Single-cell sequencing indicated cell-type-specific expression patterns of these genes across hepatic cell populations, suggesting their intricate roles in immune and liver functions within the microenvironment.

Metabolic and Liver Function Improvements

In the experimental rat model, T2DM-associated MASLD led to significant metabolic disturbances. These included elevated glucose, lipids (total cholesterol, triglycerides, low-density lipoprotein cholesterol), and inflammatory markers, alongside increased liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Palmatine treatment demonstrated significant improvements in these metabolic and liver function parameters:

• It reduced blood glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol.
• It decreased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, indicating improved liver health.
• Malondialdehyde (a marker of oxidative stress) was reduced, while antioxidant markers like superoxide dismutase and glutathione increased, suggesting a beneficial effect on oxidative stress.

Histological and Cellular Improvements

Untreated rats exhibited severe fat accumulation, inflammatory changes, and fibrosis in the liver. In contrast, palmatine-treated rats showed improved liver architecture, fewer lipid droplets, and reduced collagen deposition, demonstrating a dose-dependent improvement.

At the molecular level, palmatine significantly decreased the expression of ADRB2, BCL3, EGR1, FOS, and MAP3K8. It also reduced apoptotic proteins such as Caspase-3, Caspase-8, and Gasdermin E, indicating a substantial decrease in hepatocyte (liver cell) death. Furthermore, palmatine demonstrated anti-inflammatory effects by suppressing pro-inflammatory cytokines like tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6).

Therapeutic Potential and Limitations

Palmatine demonstrated therapeutic potential for managing MASLD associated with T2DM by targeting multiple biological pathways, improving metabolic parameters, reducing inflammation, and suppressing hepatocyte apoptosis markers.

These multi-level effects suggest palmatine as a promising candidate for complex metabolic diseases. However, it is crucial to note that this was a preclinical study conducted in rats. Its safety, efficacy, and potential for clinical use in humans require further rigorous validation and research.